Clinical Trial Update: Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating pacritinib for VEXAS syndrome (E1 ubiquitin-activating enzyme, X-linked autoinflammatory somatic syndrome) is currently recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vexas Syndrome

Drugs mentioned

• Pacritinib (pacritinib)

Snippet

Sponsor: Washington University School of Medicine | Conditions: E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic Syndrome, VEXAS | Phase 1 | Status: RECRUITING